. 2017 Aug 9;44(11):1212–1218. doi: 10.1111/1346-8138.13996

Table 1.

Selected references

Reference	Study region	Regimen	Treatment group	Subject number	Sex, male %	Age, mean	Ethnicity/race	Baseline lesion counts, mean (median), or range
Reference	Study region	Regimen	Treatment group	Subject number	Sex, male %	Age, mean	Ethnicity/race	Total	NIL	IL
Eichenfield et al. (2011)17, ^†, ^‡	USA, Canada, Belize	q.d. × 12 w	BPO 3%	328	38	20.6	White, 77%	71.6	44.6	27.0
Eichenfield et al. (2011)17, ^†, ^‡	USA, Canada, Belize	q.d. × 12 w	Vehicle	332	37	20.7	White, 78%	70.5	44.2	26.3
Gold et al. (2009)15, ^‡	USA, Puerto Rico, Canada	q.d. × 12 w	BPO 2.5%	415	50.1	18.4	White, 62.2%	(76)	(46)	(27)
Gold et al. (2009)15, ^‡	USA, Puerto Rico, Canada	q.d. × 12 w	Vehicle	418	46.9	18.0	White, 64.6%	(76)	(46)	(27)
Gollnick et al. (2009)16, ^‡	USA, Canada, Europe	q.d. × 12 w	BPO 2.5%	415	44.6	18.9	Caucasian, 79.3%	(74)	(45)	(26)
Gollnick et al. (2009)16, ^‡	USA, Canada, Europe	q.d. × 12 w	Vehicle	418	41.6	19.2	Caucasian, 79.2%	(76)	(46)	(26)
Thiboutot et al. (2008)18, ^†, ^‡	USA	q.d. × 12 w	BPO 2.5%	809	43.8	19.1	White, 73.9%	72.6	46.8	25.8
Thiboutot et al. (2008)18, ^†, ^‡	USA	q.d. × 12 w	Vehicle	395	51.4	19.4	White, 77.2%	70.2	44.0	26.1
Thiboutot et al. (2007)19, ^‡	USA	q.d. × 12 w	BPO 2.5%	149	64.4	16.5	Caucasian, 76.5%	(74)	(43)	(28)
Thiboutot et al. (2007)19, ^‡	USA	q.d. × 12 w	Vehicle	71	56.3	16.6	Caucasian, 73.2%	(78)	(46)	(29)
Leyden et al. (2001)20, ^‡	USA	b.i.d. × 10 w	BPO 5%	120	48	19	NA	49	NA	19
Leyden et al. (2001)20, ^‡	USA	b.i.d. × 10 w	Vehicle	120	40	19	NA	47	NA	19
Tschen et al. (2001)21, ^‡	USA	b.i.d. × 10 w	BPO 5%	95	46‐54	19	NA	NA	NA	23‐27
Tschen et al. (2001)21, ^‡	USA	b.i.d. × 10 w	Vehicle	48		19	NA	NA	NA	23‐27
Lookingbill et al. (1997)22, ^†, ^‡	USA	q.d. × 11 w	BPO 5%	92	49	18.5	NA	89.9	59.2	30.7
Lookingbill et al. (1997)22, ^†, ^‡	USA	q.d. × 11 w	Vehicle	58			NA	101.6	70.1	31.5
Mills Jr et al. (1986)13, ^†	USA	b.i.d. × 8 w	BPO 2.5%	25	48.4	20	NA	NA	NA	13.6
Mills Jr et al. (1986)13, ^†	USA	b.i.d. × 8 w	Vehicle	25			NA	NA	NA	13.7
Kawashima et al. (2014)9, ^†, ^‡	Japan	q.d. × 12 w	BPO 3%	178	34	21.3	Japanese	72.1	44.2	28.0
Kawashima et al. (2014)9, ^†, ^‡	Japan	q.d. × 12 w	Vehicle	182	36	22.4	Japanese	70.3	42.7	27.5
Kawashima et al. (2017)10, ^†, ^‡	Japan	q.d. × 12 w	BPO 2.5%	203	41.4	19.5	Japanese	54.9 (50)	34.7 (29)	20.1 (18)
			BPO 5%	203	38.9	20.0	Japanese	55.9 (51)	35.8 (30)	20.1 (18)
			Vehicle	201	45.3	19.2	Japanese	56.5 (51)	36.4 (30)	20.1 (18)

^‡Included in comparison of safety. ^†Included in comparison of efficacy. BPO, benzoyl peroxide; IL, inflammatory lesion; NA, not‐available; NIL, non‐inflammatory lesion; w, weeks.